trastuzumab deruxtecan + volrustomig

**Trastuzumab deruxtecan + volrustomig** is an investigational combination therapy composed of two distinct drugs: - **Trastuzumab deruxtecan (T-DXd)** is an antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2). The antibody specifically binds HER2, and is conjugated to a cytotoxic topoisomerase I inhibitor (deruxtecan) via a cleavable linker. Upon binding HER2-expressing tumor cells, it is internalized and the cytotoxic payload is released to induce cell death. - **Volrustomig (MEDI5752)** is a bispecific monoclonal antibody that simultaneously targets the programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), promoting immune activation by blocking inhibitory checkpoint pathways. The combination is being investigated as a treatment in HER2-positive cancers (notably gastric, esophageal, and non-small cell lung cancers), leveraging both direct cytotoxicity and immune-mediated antitumor response[1][2][4].

Other names

T-DXdtrastuzumab deruxtecanvolrustomigMEDI5752MEDI-5752MEDI 5752